PMID- 16050828
OWN - NLM
STAT- MEDLINE
DCOM- 20051027
LR  - 20220309
IS  - 1045-3873 (Print)
IS  - 1045-3873 (Linking)
VI  - 16
IP  - 7
DP  - 2005 Jul
TI  - Predictors of atrial antitachycardia pacing efficacy in patients affected by 
      brady-tachy form of sick sinus syndrome and implanted with a DDDRP device.
PG  - 714-23
AB  - Predictors of ATP efficacy in brady/tachy patients. BACKGROUND: Recent options to 
      treat atrial tachyarrhythmias (ATA) include implantable devices delivering 
      antitachycardia pacing therapies (ATP). No prospective study selected patients 
      with higher chances of episode termination by ATP or indicated the most effective 
      ATP use. Our aim was to study ATP efficacy in patients with brady-tachy form of 
      sinus node disease (SND), identifying clinical factors, ATA characteristics, and 
      device features predicting ATP efficacy. METHODS AND RESULTS: Three hundred and 
      sixteen patients (105 M, aged 71.1+/-8.8 years) received a DDDRP pacemaker and 
      were prospectively followed. Median follow-up was 18 months: 37,125 ATA episodes 
      occurred in 217 patients; ATP treated 5,536 of them. Overall, ATP efficacy was 
      50.0%. A multivariate analysis identified longer arrhythmia cycle lengths 
      (OR=1.25; CI=1.07-1.47) and shorter delays to ATP delivery (OR=0.15; 
      CI=0.10-0.22) as independent predictors of ATP efficacy for episodes preceded by 
      >or=5 minutes of sinus rhythm. Additionally, ATP efficacy for all treated 
      episodes was predicted by lower New York Heart Association (NYHA) class (OR=0.64; 
      CI=0.42-0.98), episode classification as nonimmediate recurrence of ATA 
      (non-IRAT) (OR=0.07; CI=0.02-0.33), absence of overlap in the device detection 
      windows (OR=0.54; CI=0.32-0.91), and flecainide treatment (OR=2.22; 
      CI=1.04-4.71). CONCLUSIONS: In patients paced for SND, multivariate analysis 
      shows that ATP efficacy is associated to longer arrhythmia cycle lengths, shorter 
      ATP delivery delays, NYHA class I, episode classification as non-IRAT, absence of 
      overlap in the atrial arrhythmia device detection windows, and flecainide 
      treatment.
FAU - Boriani, Giuseppe
AU  - Boriani G
AD  - Institute of Cardiology, University of Bologna and Azienda Ospedaliera, 
      S.Orsola-Malpighi, Bologna, Italy. cardio1@med.unibo.it
FAU - Padeletti, Luigi
AU  - Padeletti L
FAU - Santini, Massimo
AU  - Santini M
FAU - Gulizia, Michele
AU  - Gulizia M
FAU - Capucci, Alessandro
AU  - Capucci A
FAU - Botto, Gianluca
AU  - Botto G
FAU - Ricci, Renato
AU  - Ricci R
FAU - Molon, Giulio
AU  - Molon G
FAU - Accogli, Michele
AU  - Accogli M
FAU - Vicentini, Alfredo
AU  - Vicentini A
FAU - Biffi, Mauro
AU  - Biffi M
FAU - Vimercati, Marco
AU  - Vimercati M
FAU - Grammatico, Andrea
AU  - Grammatico A
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Cardiovasc Electrophysiol
JT  - Journal of cardiovascular electrophysiology
JID - 9010756
RN  - 0 (Anti-Arrhythmia Agents)
SB  - IM
CIN - J Cardiovasc Electrophysiol. 2005 Jul;16(7):724-6. PMID: 16050829
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Arrhythmia Agents/therapeutic use
MH  - Cohort Studies
MH  - Humans
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - *Pacemaker, Artificial
MH  - Predictive Value of Tests
MH  - Prospective Studies
MH  - Sick Sinus Syndrome/*physiopathology/*therapy
MH  - Treatment Outcome
EDAT- 2005/07/30 09:00
MHDA- 2005/10/28 09:00
CRDT- 2005/07/30 09:00
PHST- 2005/07/30 09:00 [pubmed]
PHST- 2005/10/28 09:00 [medline]
PHST- 2005/07/30 09:00 [entrez]
AID - JCE40716 [pii]
AID - 10.1111/j.1540-8167.2005.40716.x [doi]
PST - ppublish
SO  - J Cardiovasc Electrophysiol. 2005 Jul;16(7):714-23. doi: 
      10.1111/j.1540-8167.2005.40716.x.